Perimenopause in Brain Aging and Alzheimer's Disease

$1,970,713P01FY2015AGNIH

University Of Southern California, Los Angeles CA

Investigators

Linked publications & trials

Paper 38902275 Paper 38501109 Paper 38487578 Paper 38448497 Paper 38206365 Paper 38026173 Paper 37937120 Paper 36959514 Paper 36837905 Paper 36787293 Paper 36543814 Paper 36495935 Paper 36325137 Paper 36206387 Paper 35928995 Paper 35601622 Paper 35356299 Paper 34997690 Paper 34929348 Paper 34870371 Paper 34732544 Paper 33969178 Paper 33615942 Paper 33406436 Paper 33319170 Paper 33294859 Paper 33283039 Paper 33090701 Paper 32963231 Paper 32828189 Paper 32736000 Paper 32709961 Paper 32632771 Paper 32618421 Paper 32580974 Paper 32472577 Paper 32444841 Paper 32431604 Paper 32388179 Paper 32236399 Paper 32211509 Paper 32207833 Paper 32143551 Paper 32130251 Paper 32123170 Paper 32049929 Paper 32047612 Paper 31969828 Paper 31917799 Paper 31902950 Paper 31803046 Paper 31677936 Paper 31664643 Paper 31567873 Paper 31362877 Paper 31110493 Paper 30997482 Paper 30837858 Paper 30555318 Paper 30540774 Paper 30509127 Paper 30497015 Paper 30478117 Paper 30446421 Paper 30396359 Paper 30356809 Paper 30298183 Paper 30298180 Paper 30242290 Paper 30091648 Paper 29975287 Paper 29925037 Paper 29574441 Paper 29574399 Paper 29370871 Paper 29016679 Paper 28855400 Paper 28701949 Paper 28575011 Paper 27996108 Paper 27870425 Paper 27757081 Paper 27651175 Paper 27546867 Paper 27357142 Paper 27183047 Paper 27154981 Paper 27143423 Paper 26973115 Paper 26969397 Paper 26844268 Paper 26792520 Paper 26708713 Paper 26686669 Paper 26217222 Paper 26150507 Paper 26007613 Paper 25921624 Paper 25534394 Paper 25533426

Abstract

DESCRIPTION (provided by applicant): Each year ~1.5 million American women between ages of 45 and 55 enter into the perimenopause. Yet to be discovered is the impact perimenopause has on key brain regions involved in cognition and known to be vulnerable to Alzheimer's disease (AD). Women have a higher lifetime risk of developing AD and represent more than 60% of the Alzheimer's disease population. The mission of our Perimenopause in Brain Aging and Alzheimer's Disease Program Project is to discover the biological transformations that occur in the brain during the perimenopausal transition that can result in phenotypes at risk for development of Alzheimer's pathology. We seek to identify the mechanisms by which these changes occur and to translate these discoveries to determine the optimal timing and strategies for preventing conversion to the perimenopausal at-AD-risk phenotype. To achieve our mission, we have developed a focused research center model with an integrated set of four Projects and three Cores. Projects 1, 2 and 3 are basic, mechanistic and preclinical translational science investigations of the perimenopausal brain utilizing our program developed rodent models of human perimenopause. Project 4 uses the results of Project 1, 2 and 3 to inform its ancillary association analysis of existing data and samples from the NIA-funded clinical trial Early versus Late Intervention Trial with Estrogen (ELITE) (R01AG-024154). To achieve our Program mission, each project has a unique but complementary research focus with all Aims of all projects and cores addressing Program wide aims. Innovative and integrative features of our Program include: bidirectional translational research; rodent models of human perimenopause transition; custom designed gene arrays that include GWAS identified AD risk factor genes and bioenergetic, inflammatory and AD system pathways, shared customized data and document management. Program-wide gene array and bioinformatic analyses across all projects. Discovery of at-AD-risk phenotypes and the underlying mechanisms of phenotype development could potentially lead to the early identification of those at greatest risk for developing AD and mechanistically inform interventions to prevent the disease. Program research addresses NIA Strategic Goals A and C.

View original record on NIH RePORTER →